Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-Per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

Journal of Clinical Oncology - United States
doi 10.1200/jco.2014.57.0572
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

P2-033Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel Dose Dense in Stage III Breast Cancer

Annals of Oncology
MedicineOncologyHematology
2018English

A Feasibility Study of Bevacizumab Plus Dose-Dense Doxorubicin-Cyclophosphamide (AC) Followed by Nanoparticle Albumin-Bound Paclitaxel in Early-Stage Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2011English

Axillary Management of Stage II/III Breast Cancer in Patients Treated With Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative)

Journal of the American College of Surgeons
Surgery
2017English

Fifteen-Year Median Follow-Up Results After Neoadjuvant Doxorubicin, Followed by Mastectomy, Followed by Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) Followed by Radiation for Stage III Breast Cancer: A Phase II Trial (CALGB 8944)

Breast Cancer Research and Treatment
Cancer ResearchOncology
2008English

Positive Response to Neoadjuvant Cyclophosphamide and Doxorubicin in Topoisomerase II Nonamplified/Her2/Neu Negative/Polysomy 17 Absent Breast Cancer Patients

Cancer Management and Research
Oncology
2010English

Cisplatin Versus Carboplatin in Combination With Paclitaxel as Neoadjuvant Regimen for Triple Negative Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2017English

Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer With Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02)

Frontiers in Oncology
Cancer ResearchOncology
2018English

High Expression of Class III Β-Tubulin Predicts Good Response to Neoadjuvant Taxane and Doxorubicin/Cyclophosphamide-Based Chemotherapy in Estrogen Receptor–Negative Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2013English

Hormone Receptor-Negative as a Predictive Factor for Pathologic Complete Response to Neoadjuvant Therapy in Breast Cancer

Einstein (São Paulo, Brazil)
Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy